KUALA LUMPUR, May 17 (Bernama) — Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company has announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being co-developed by Baylor College Medicine and Tessa.
The data is from an ongoing Phase 1 dose-escalation study (NCT04288726) testing TT11X in patients with CD30+ lymphomas. The results have been presented at the 24th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021).
The presentation at ASGCT 2021 highlighted data from six patients treated with the therapy. The results demonstrated a favourable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients.
Full findings from the trial are expected to be reported by year-end, according to a statement.
“This is early but significant data supporting development of Tessa’s ‘off-the-shelf,’ allogeneic cell therapy,” said Tessa Therapeutics President and Chief Executive Officer, Jeffrey H. Buchalter.
“We believe there is an enormous potential for our allogeneic CD30-CAR EBVST platform, and we remain committed to our longer-term plan to develop this platform to tackle both hematologic malignancies and solid tumours where there is significant patient need.”
Tessa is developing a proprietary allogeneic cell therapy platform based on decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by Tessa’s Scientific Co-Founder, Dr Malcolm Brenner, and the team at Baylor College of Medicine.
VSTs are highly specialised T cells with the ability to recognise and kill infected cells while activating other parts of the immune system for a coordinated response.
With this platform approach, Tessa aims to overcome the current challenges faced by allogeneic cell therapies and create more efficacious, reliable, and scalable therapies capable of targeting a broad range of cancers.
More details at www.tessacell.com.
— BERNAMA
wonderland 